Abstract
The recognition of low malignant potential (LMP) or borderline ovarian tumors as a distinct pathological entity by the International Federation of Gynecology and Obstetrics was an attempt to add a needed degree of precision to the diagnosis of ovarian tumors [1]. Despite this widely accepted improvement in histological diagnostic criteria, the behavior and prognosis of LMP tumors remain unpredictable and the appropriate treatment continues to be debated. The uncertainty in therapeutic decision making is complicated by several factors. The diagnosis of an LMP tumor is rarely made preoperatively, so the initial treatment plan is often made in the operating room by physicians unaccustomed to treating ovarian malignancies. Consultation with clinicians more experienced with these tumors is frequently not feasible. In addition, histological diagnosis by rapid frozen section of LMP tumors is often difficult and unreliable. Finally, the postoperative treatment of LMP tumors in the United States has been characterized by a wide variety of regimens, making comparisons of long term outcomes difficult.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
